Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved palbociclib in combination with fulvestrant as a treatment option for the treatment of patients who are women with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have received prior endocrine therapy.
This is written in the approval document as:
Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant in women who have received prior endocrine therapy
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| HSE (1) | ER positive, HER2-negative | Invasive Breast Carcinoma | Fulvestrant, Palbociclib | |
| HSE (1) | HER2-negative, PR positive | Invasive Breast Carcinoma | Fulvestrant, Palbociclib | |
| HSE (1) | ER positive, HER2-negative, PR positive | Invasive Breast Carcinoma | Fulvestrant, Palbociclib |